ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $8.4M of Roivant Sciences Ltd.
Sold$8,449,810
$29.16Price
289,774Shares
−2%Stake
What ROIV did after the filing
- The stock from Tue, Apr 21 open, $29.03
- −1.1%
- S&P 500, same days
- +6.2%
Measured over 30 trading days, to the Jun 3 close.
Traded Thu, Apr 16. Filed Mon, Apr 20, 6:27 PM ET, after the close. Returns use the Apr 21 open and the Jun 3 close. Not investment advice.